The goal of the UNC SPORE is to reduce breast cancer mortality and incidence in North Carolina through an interdisciplinary program of research and intervention that: 1. Integrates efforts in cancer prevention and control, molecular epidemiology, clinical research, and laboratory sciences; and 2. Targets behavioral and biologic issues relevant to African American women. The six primary objectives of the UNC SPORE are to: 1. Identify the determinants of the Black/White gap in breast cancer mortality in North Carolina, and then to use novel community and provider interventions to increase early detection and eliminate the gap; 2. Initiate a long-term, population-based study of breast cancer etiology in a defined North Carolina population containing 630,000 women aged 20- 74, 29% of whom are African American; 3. Combine molecular biology and epidemiology in the investigation of the environmental and genetic determinants to breast cancer in African American and White women in the defined population; 4. Develop new clinical markers for neoplastic proliferation of breast cancer cells through the discovery of new genes: 5. Promote new translational research projects and recruit new investigators to breast cancer research; and 6. Complement the NCI and other SPOREs in the national effort to reduce breast cancer mortality and incidence by focusing in on minority issues, development and use of novel molecular epidemiologic approaches, and the development of public health research programs in breast cancer and control.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-06
Application #
2458083
Study Section
Special Emphasis Panel (SRC (27))
Project Start
1992-09-30
Project End
2000-07-31
Budget Start
1997-08-05
Budget End
1998-07-31
Support Year
6
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820

Showing the most recent 10 out of 598 publications